Israel's pharmaceutical company Zion Medical, which recently broke the news of a first successful clinical trial of what they called HIV treatment, issued an additional Twitter statement, making it clear that more studies and official results will be needed of these will have to be published and revised.
Since the company made the announcement on October 31, there was a surge of emotion, especially with regard to social environments, while people asked for more information about "potential treatment."
According to the World Health Organization, by the end of 2017, about 36.9 million people worldwide were living with HIV.
In a statement at that time, Zion Medical announced the results of the first clinical trial of Gammora HIV, which, according to the company, removed up to 99% of the HI virus within four weeks of treatment.
Nine HIV-infected patients participated in "Part I and II" of the study at Dr. Ronald Bata Memorial Hospital in Entebbe for more than 10 weeks.
But the company moved to temper, saying on Twitter: "We want to thank everyone for their interest in the promising results of our first clinical trial. Like you, we hope that #Gammora could one day give HIVIs a viable way to get rid of the infection. on this mission, including additional studies, publication of results, and steps to make #Gammora available in the trade.
"We are not there yet, but we are a step closer, we hope – and we are determined to inform you of our progress."
The company also acknowledged that official results should be reviewed by a college in a scientific journal, which it hopes to do in early 2019.
Professor Adrian Puren, head of the HIV and Serum-Molecular Surveillance Section at the National Institute for Communicable Diseases (NICD), told Health24 that there is a long process to be followed before being bold enough to call his healing drug potential.
"You will have to go through several stages to prove something like this. It is important to research, collect evidence and build all that is necessary to find potential.
"There are different phases that you should move in. You may need to do an animal study, then a small human process – the process is complex and you may have to start really small and do more many tests to establish that the drugs are not toxic and that there are no harmful side effects.
"You should also test the efficacy of drugs at different stages, going through the different phases of the studies at a certain stage, also have to carry out randomized trials so as to eliminate prejudices from research and make sure you injured.
"Passing through something like this is not easy, it's very complex, it has to be detailed and it's pretty expensive." If I wanted to look at this medicine, I would like to see the published literature and I can trace all the authors back, knowing that everything has been revised.
"Once all the research has been done, reviewed and conducted through all the regulatory authorities, the various ethics committees and has been sufficiently examined, then a company will be able to make such a statement. I usually do it at big conferences, "Puren said.
Deputy Director of the Department of Health for HIV / AIDS, TB and maternity, child and woman health, Dr. Yogan Pillay, added: "As far as we know, there are no published clinical trials.
"Unless this is published in peer-reviewed journals and the World Health Organization has approved this drug, we can not take this statement seriously."
On Tuesday, a prominent HIV scientist killed the "cure" that was widely spread in the social media as a blow to the head.
"The HIV virus has been in various forms for decades – unfortunately, this does more," Professor Francois Venter of the University of Witwatersrand for Reproductive Health and HIV told Health News.
He said by saying that the drug is a potential remedy without the side effects being "higher biological claims occurring in public before official literature [is published] and should be viewed with profound skepticism. "
"I looked at the press report and the company website, and even if you think their claims are many years from testing them," Venter said.
Zion Medical is a relatively new company, set up in 2014. According to the company's website, it develops healing products for AIDS and Cancer based on HIV-derived peptides and target lentivirus particles.
He lists his partners as the Hebrew University of Jerusalem, the Mount Sinai Hospital in New York (USA) and the Sourasky Tel-Aviv Medical Center, among others.
All of the Health24 attempts to contact Zion Medical directly for additional comments have been unsuccessful so far – all forms of e-mail have been unsuccessful due to an invalid email address and all phone calls have not responded.